RNA Analytical/Quality Videos

31. The Challenges Novel Lipids Pose For mRNA-LNP Manufacturing 2/24/2026

    Though there are a lot of exciting advancements being made with novel lipid chemistries, CMC Consultant Sujit Jain provides an important reality check for us: These innovations break established platforms, requiring fresh process development, complex impurity profiling, and new vendor qualifications.

32. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

    In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

33. A Double-Edged Sword? Defining "Efficiency" In mRNA Process Development 8/22/2024

    In this clip from a recent Advancing RNA LIVE event, panelists address a question about where the best opportunities exist upstream and/or downstream to increase mRNA manufacturing efficiencies.

34. How Analytical Development Is Informing mRNA Process Development Today 8/22/2024

    In this clip, Advancing RNA LIVE, panelists, share their perspectives on how advancements in RNA analytical development are complementing and informing process development efforts for linear mRNA.

35. Navigating the Continuum of LNP Analytical Knowledge 6/9/2026

    In this clip, Advancing RNA Live speakers Elaine Peters, Philippe Talaga, and Ilya Shestopalov advocate for an orthogonal approach as we strive to better understand our LNP QAs — with particular attention paid to particle size.   

36. Crafting A "Durable" Partnership: A Two-Pronged Approach

    Featured speakers for the "Got Raw Materials? The State Of The mRNA Supply Chain" event share how they are working to deepen their partnerships today.

37. Engaging Early In Process Development To Bring mRNA Sequences To Life

    Examine why template sequence characteristics are relevant for cGMP manufacturing of high-quality mRNA and consider insights on how to develop a scalable, robust, and economically viable process.

38. Improving IVT Processes: Addressing Analytical Limitations & PAT Shortcomings 4/11/2025

    Advancing RNA Live panelists identify what is “as good as we can get right now” in terms of understanding our IVT reactions while sharing their ideas on how we can arrive at a future that includes real-time monitoring of our drug substance production processes.

39. Beyond Purity: Addressing the FDA's CMC Expectations for gRNA 4/29/2026

    Advancing RNA Live panelists Venkat Krishnamurthy, April Sena, and Max De Long share their perspectives on the most important regulatory considerations for gRNA production utilizing an enzymatic ligation approach.

40. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?